X4 Pharmaceuticals Inc.

NASDAQ: XFOR
Share price (3/25/25): $0.26
Market cap (3/25/25): $44.2 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Registration of securities for employees

Registration of securities for employees

Registration of securities for employees

Registration of securities for employees

Shelf registration

Ownership Filter

Arbet-Engels Christophe

Mostafa Adam S.

News Filter

Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals and Norgine Enter Into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Announces Positive Results From Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

Proxies Filter

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission

Notice of effectiveness